Stay updated on Adagrasib Combo in KRAS G12C Clinical Trial
Sign up to get notified when there's something new on the Adagrasib Combo in KRAS G12C Clinical Trial page.

Latest updates to the Adagrasib Combo in KRAS G12C Clinical Trial page
- Check6 days agoChange DetectedThe study record has been expanded with numerous new global locations and investigators, increasing the reach to 770 locations and updating site details and contacts. At the same time, several existing site entries and contacts were removed or changed, reflecting a cleanup or reorganization of local institutions.SummaryDifference0.3%

- Check30 days agoChange DetectedNew recruitment locations and site contacts have been added (e.g., Teresa Garcia Manrique in Seville; Saitama Medical University International Medical Center; Gleneagles Penang), expanding the study's recruitment footprint. The total number of locations is updated to 767.SummaryDifference0.2%

- Check37 days agoChange DetectedThe page revision tag was updated to Revision: v3.5.4, replacing the previous v3.5.3. This indicates the page version was updated, likely including minor edits or fixes without changing the study details.SummaryDifference0.0%

- Check52 days agoChange DetectedNew study locations were added: Liuzhou, Guangxi, China (545006) and Taoyuan, Taiwan (333); Liuchow, Guangxi, China (545006) and Taoyuan District, Taiwan (333) were removed. The page revision updated to v3.5.3.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page revision label was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check80 days agoChange DetectedUpdated the study location listing from Padua, Italy 35128 to Padova, Italy 35128.SummaryDifference0.0%

Stay in the know with updates to Adagrasib Combo in KRAS G12C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib Combo in KRAS G12C Clinical Trial page.